Salvatore Siena

Salvatore Siena is full professor of Medical Oncology at Università degli Studi di Milano (La Statale) and director of Niguarda Cancer Center, Department of Hematology and Oncology, and Falck Division of Oncology at Grande Ospedale Metropolitano Niguarda in Milan, Italy. He received a degree of Doctor of Medicine and Surgery at Università degli Studi di Pavia and post-doctoral training at Ospedale Policlinico San Matteo, Pavia, I, Memorial Sloan-Kettering Cancer Center, New York, NY, and Fred Hutchinson Cancer Research Center, Seattle, WA. He had tenured positions from 1984 to 1997 at Istituto Nazionale Tumori, Milan, I, from 1997 to 1988 at Istituto Clinico Humanitas, Milan, I, and from 1999 to present at Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano, Milan, I. He is committed to clinical care of adult solid tumors and to research and development of novel therapies: Research programs comprise mostly phase I-II clinical studies that focus on epithelial tumors especially colon, rectum, lung, and other solid tumors. Results and discoveries are published in scientific articles listed in https://pubmed.ncbi.nlm.nih.gov with 49467 citations and 89 h-index (Scopus). His research is supported by competitive grants awarded by European Community; Fondazione AIRC (Associazione Italiana Ricerca Cancro); Fondazione Oncologia Niguarda ; Ministero Salute; and Fondazione Regionale Ricerca Biomedica of Regione Lombardia. For research he collaborates with clinical and pre-clinical investigators at Grande Ospedale Metropolitano Niguarda, Università degli Studi di Milano, and at other Institutions in the world, mainly at Università degli Studi di Torino, Istituto FIRC di Oncologia Molecolare (IFOM), Istituto Nazionale Genetica Molecolare (INGM), Vall d'Hebron Institute of Oncology, European Institute of Oncology (IEO), and at biotech and pharmaceutical organizations. Advances and discoveries with impact on clinical practice encompass a) the mobilization and transplantation of blood stem cells (1989); b) the role of RAS and BRAF mutations for EGFR-targeted therapies (2007), and c) the development of treatments for colorectal cancer and other malignancies such as therapies that target EGFR, BRAF, HER2, BRAF, ROS1, and NTRK actionable alterations (from 2004 to present). Principal investigator or co-investigator of studies leading to registration and clinical practice guidelines of the following therapies: cyclophosphamide and cytokines for mobilization and transplantation of blood stem cells, 1989; darbepoetin for solid tumors, 2002; peg-filgrastim for solid tumors, 2003; cetuximab for colorectal cancer, 2004; panitumumab for colorectal cancer, 2007; denosumab for solid tumors, 2010; regorafenib for colorectal cancer, 2015; sorafenib for thyroid cancer, 2014; nab-paclitaxel for pancreatic cancer, 2013; trastuzumab lapatinib doublet for colorectal cancer, 2015; trifluridine tipiracil for colorectal cancer, 2017; binimetinib/encorafenib/cetuximab triplet for colorectal cancer, 2019; entrectinib for ROS1- and NTRK-fusion positive tumors, 2019; trastuzumab deruxtecan for colorectal cancer, 2021. Since 2015 Thomson Reuters/Clarivate Analytics recognizes Salvatore Siena among the World’s Most Influential Scientific Minds and Highly Cited Researchers. He serves as a member of the Scientific Advisory Board of Fondazione Istituto Nazionale Genetica Molecolare (INGM), of the Gastro-Intestinal Tumors Faculty Group of European Society Medical Oncology (ESMO), and as president of Fondazione Oncologia Niguarda. In 2020 Salvatore Siena was awarded the Premio FIRC Guido Venosta presented by Sergio Mattarella, President of Italian Republic.